BLPH VS BIOL Stock Comparison

Performance

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

BIOL
10/100

BIOL returned -99.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

BIOL
88/100

2 analysts offer 12-month price targets for BIOL. Together, they have an average target of 0, the most optimistic target put BIOL at 0 within 12-months and the most pessimistic has BIOL at 0.

Technicals

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

BIOL
14/100

BIOL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

BIOL
10/100

BIOL has missed earnings 12 times in the last 20 quarters.

Profit

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

BIOL
10/100

Out of the last 20 quarters, BIOL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

BIOL
54/100

BIOL has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Biolase, Inc. Summary

Nasdaq / BIOL

Healthcare

Medical - Devices

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Power up your portfolio